Cargando…
Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications
Biopolymeric chitosan structure (Cs) is rationally investigated owing to its potentiality in pharmaceutical applications. The synthetic routes of biomimetic Cs-based blend electrospun nanofibers were studied. Herein, biocompatible crosslinked electrospun polyvinyl alcohol (PVA)/Cs-reduced gold nanop...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693921/ https://www.ncbi.nlm.nih.gov/pubmed/33126627 http://dx.doi.org/10.3390/pharmaceutics12111029 |
_version_ | 1783614857422045184 |
---|---|
author | Teaima, Mahmoud H. Abdelnaby, Fatma A. Fadel, Maha El-Nabarawi, Mohamed A. Shoueir, Kamel R. |
author_facet | Teaima, Mahmoud H. Abdelnaby, Fatma A. Fadel, Maha El-Nabarawi, Mohamed A. Shoueir, Kamel R. |
author_sort | Teaima, Mahmoud H. |
collection | PubMed |
description | Biopolymeric chitosan structure (Cs) is rationally investigated owing to its potentiality in pharmaceutical applications. The synthetic routes of biomimetic Cs-based blend electrospun nanofibers were studied. Herein, biocompatible crosslinked electrospun polyvinyl alcohol (PVA)/Cs-reduced gold nanoparticles (Cs(Rg))/β-CD (beta-cyclodextrin) in pure water were fabricated. To this end, supportive PVA as a carrier, Cs bio modifier, and gold reductant and β-CD as smoother, inclusion guest molecule, and capping agent exhibit efficient entrapment of moxifloxacin (Mox) and consequently accelerate release. Besides, PVA/Cs(Rg)/β-CD paves towards controlled drug encapsulation-release affinity, antimicrobial, and for wound dressing. Without losing the nanofiber structure, the webs prolonged stability for particle size and release content up to 96.4%. The synergistic effect of the nanoformulation PVA/Cs(Rg)/β-CD against pathogenic bacteria, fungus, and yeast, including Staphylococcus aureus, Escherichia coli, Candida albicans, and Aspergillus niger, posed clear zones up to 53 φmm. Furthermore, a certain combination of PVA/Cs (Rg)/β-CD showed a total antioxidant capacity of 311.10 ± 2.86 mg AAE/g sample. In vitro cytotoxicity assay of HePG2 and MCF-7 NF6 can eradicate 34.8 and 29.3 µg/mL against selected cells. |
format | Online Article Text |
id | pubmed-7693921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76939212020-11-28 Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications Teaima, Mahmoud H. Abdelnaby, Fatma A. Fadel, Maha El-Nabarawi, Mohamed A. Shoueir, Kamel R. Pharmaceutics Article Biopolymeric chitosan structure (Cs) is rationally investigated owing to its potentiality in pharmaceutical applications. The synthetic routes of biomimetic Cs-based blend electrospun nanofibers were studied. Herein, biocompatible crosslinked electrospun polyvinyl alcohol (PVA)/Cs-reduced gold nanoparticles (Cs(Rg))/β-CD (beta-cyclodextrin) in pure water were fabricated. To this end, supportive PVA as a carrier, Cs bio modifier, and gold reductant and β-CD as smoother, inclusion guest molecule, and capping agent exhibit efficient entrapment of moxifloxacin (Mox) and consequently accelerate release. Besides, PVA/Cs(Rg)/β-CD paves towards controlled drug encapsulation-release affinity, antimicrobial, and for wound dressing. Without losing the nanofiber structure, the webs prolonged stability for particle size and release content up to 96.4%. The synergistic effect of the nanoformulation PVA/Cs(Rg)/β-CD against pathogenic bacteria, fungus, and yeast, including Staphylococcus aureus, Escherichia coli, Candida albicans, and Aspergillus niger, posed clear zones up to 53 φmm. Furthermore, a certain combination of PVA/Cs (Rg)/β-CD showed a total antioxidant capacity of 311.10 ± 2.86 mg AAE/g sample. In vitro cytotoxicity assay of HePG2 and MCF-7 NF6 can eradicate 34.8 and 29.3 µg/mL against selected cells. MDPI 2020-10-28 /pmc/articles/PMC7693921/ /pubmed/33126627 http://dx.doi.org/10.3390/pharmaceutics12111029 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Teaima, Mahmoud H. Abdelnaby, Fatma A. Fadel, Maha El-Nabarawi, Mohamed A. Shoueir, Kamel R. Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications |
title | Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications |
title_full | Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications |
title_fullStr | Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications |
title_full_unstemmed | Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications |
title_short | Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications |
title_sort | synthesis of biocompatible and environmentally nanofibrous mats loaded with moxifloxacin as a model drug for biomedical applications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693921/ https://www.ncbi.nlm.nih.gov/pubmed/33126627 http://dx.doi.org/10.3390/pharmaceutics12111029 |
work_keys_str_mv | AT teaimamahmoudh synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications AT abdelnabyfatmaa synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications AT fadelmaha synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications AT elnabarawimohameda synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications AT shoueirkamelr synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications |